SCM
SBBP

Segantii Capital Management’s Strongbridge Biopharma plc. SBBP Stock Holding History

Segantii Capital Management’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,600
Closed -$36K – 319
2017
Q1 		$36K Buy
+7,600
New +$23.3K 0.01% 326

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
TAF
Tredje AP-fonden Se-111 91 Stockholm, Sweden $22.1B AUM 41.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Segantii Capital Management's SBBP Position: Q2 2017 in Review

Segantii Capital Management sold out of Strongbridge Biopharma plc. (SBBP) in Q2 2017, closing a stake of 7,600 shares — an estimated $36K sold.

Segantii Capital Management first reported a position in SBBP in Q1 2017 and held it in 1 quarter. The position peaked at $36K in Q1 2017. 38 funds tracked by Wall St. Rank hold SBBP as of Q2 2017.

  • Segantii Capital Management reported no remaining Strongbridge Biopharma plc. position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 7,600 Strongbridge Biopharma plc. shares in Q2 2017, an estimated $36K.
  • Segantii Capital Management first reported a position in Strongbridge Biopharma plc. in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Strongbridge Biopharma plc. position peaked at $36K in Q1 2017.
  • 38 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.